Atosiban versus placebo in the treatment of threatened preterm birth between 30 and 34 weeks gestation: Study protocol of the 4-year APOSTEL 8 follow-up
Larissa Van Der Windt*, Job Klumper, Emilie V.J. Van Limburg Stirum, Janneke Van 'T Hooft, Madelon Van Wely, Aleid G. Van Wassenaer-Leemhuis, Eva Pajkrt, Martijn A. Oudijk, M. A. De Boer, E. S.A. Van Den Akker, A. J.M. Huisjes, J. M. Sikkema, J. Schaaf, H. Visser, D. W.M. Papatsonis, J. J. Zwart, J. O.E.H. Van Laar, J. Baalman, K. S.J. Gordijn, D. P. Van Der HamK. C. Vollebregt, J. Langenveld, M. S. Post, M. Sueters, H. C.J. Scheepers, R. R. Scholten, N. Van Gemund, M. N. Bekker, Deurloo, M. Knol, F. McAuliffe, K. Walker, APOSTEL 8 Study Group
Research output: Contribution to journal › Article › Academic › peer-review
Fingerprint
Dive into the research topics of 'Atosiban versus placebo in the treatment of threatened preterm birth between 30 and 34 weeks gestation: Study protocol of the 4-year APOSTEL 8 follow-up'. Together they form a unique fingerprint.